Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. SHPG has maintained this ranking for 11 months.

Shire plc (NASDAQ:SHPG) is a constituent of the 350 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. SHPG's market value is $44.8 billion which places it in the top 10% of its industry group. The current Portfolio Grader ranking for SHPG puts it 233 among the 350 companies in this industry group, which is a below-average position; in the third quartile of the sector with a ranking of 538 among the 782 companies in the sector, and number 3,229 in the nearly 5,000 company Portfolio Grader universe.

With a $44.7 billion market value, Shire plc (NASDAQ:SHPG) ranks in the top decile in its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, in market value. From the vantage point of investment attractiveness, the ranking for SHPG by Portfolio Grader places it 216 among the 349 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 521 among the 781 companies in the sector, and number 3,243 in the nearly 5,000 company Portfolio Grader universe.

Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's investing system and his Portfolio Grader stock evaluator. SHPG has maintained this ranking for 11 months.

Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's approach to investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking SHPG has had from Portfolio Grader for 11 months.

Currently, Shire plc (NASDAQ:SHPG) has a Sell using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. SHPG has maintained this ranking for 11 months.

Shire plc (NASDAQ:SHPG) is one of 347 companies within the Biotechnology GICS industry group, which is in turn part of the 783 company GICS Health Care sector. SHPG's market value is $43.0 billion which places it in the top 10% of its industry group. The current Portfolio Grader ranking for SHPG puts it 242 among the 347 companies in this industry group, which is a below-average position; in the third quartile of the sector with a ranking of 564 among the 783 companies in the sector, and number 3,660 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks Shire plc (NASDAQ:SHPG) a Sell. The system for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking SHPG has had from Portfolio Grader for 11 months.

Shire plc (NASDAQ:SHPG) is a $46.6 billion in market value component of the Biotechnology GICS industry group where the stock's Portfolio Grader ranking currently places it 285 among the 344 companies in this industry group, a spot that is well below-average. SHPG is ranked squarely in the bottom quartile of the sector with a ranking of 655 among the 783 companies in the sector and number 4,081 in the 5000 company Portfolio Grader company universe.

Shire plc (NASDAQ:SHPG) is ranked as a Sell using Louis Navellier's investing system and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking SHPG has had from Portfolio Grader for 11 months.